Getting to the Tumor: Beyond the First Generation of Tumor Targeting Technologies

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
In oncology, going beyond the current standard of care will require increasingly potent therapies - drugs that must target to the tumor microenvironment. First generation technologies such as antibody drug conjugates (ADCs) have enabled some degree of selective delivery of anticancer agents to tumor cells, but this first generation leaves room for improvement. During this panel, senior leaders from biotech and big pharma companies will discuss how they overcome skepticism about tumor targeting technologies, how they see the field evolving and what impact they believe these technologies will have on the evolution of oncology treatment across tumor types.
Moderator
photo
VP, Corporate Development and Commercial Strategy
Cybrexa Therapeutics
Speakers
photo
CEO
Cybrexa Therapeutics
photo
CEO
Bicycle Therapeutics
photo
CEO
Kleo Pharmaceuticals, Inc.
photo
Executive Director, Discovery Biotherapeutics
Bristol Myers Squibb
photo
Co-Founder, President, Chief Executive Officer, and Chairman
Silverback Therapeutics